Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

DNA-dependent protein kinase-targeting siDNA DT01

A proprietary preparation of small interfering DNA (siDNA) molecules with potential chemo/radiosensitizing activity. By mimicking DNA double strand breaks (DSBs), DNA-dependent protein kinase-targeting siDNA DT01 inhibits the non-homologous end joining (NHEJ) process, one of the main DNA repair mechanisms, via binding to and activating DNA-dependent protein kinase (DNA-PK), a core component of the NHEJ complex. DNA-PK activation causes hyper-phosphorylation of histone variant H2AX on DNA and results in a different phosphorylated pattern of H2AX upon ionizing radiation treatment. This ultimately interferes with the repair of DNA DSBs during chemo- or radiotherapy, thereby increasing tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy.
Synonym:DNA-PK-targeting siDNA DT01
Code name:DT01
Search NCI's Drug Dictionary